Delving into the Latest Updates on Nesiritide Recombinant with Synapse

Overview

Basic Info

Drug Type

Recombinant polypeptide

Synonyms

BNP, Brain natriuretic peptide, Brain natriuretic peptide 32

+ [11]

Target

NPRA

Action

agonists

Mechanism

NPRA agonists(Natriuretic peptide receptor 1 agonists)

Therapeutic Areas

Cardiovascular DiseasesRespiratory DiseasesUrogenital Diseases+ [1]

Active Indication-

Inactive Indication

Acute congestive heart failureAcute decompensated heart failureAcute Kidney Injury+ [15]

Originator Organization

Johnson & Johnson

Active Organization-

Inactive Organization

Scios, Inc.

Chengdu Shengnuo Biotechnology Co., Ltd.Janssen-Cilag Pty Ltd.

+ [3]

License Organization

Scios, Inc.

Johnson & Johnson

Drug Highest PhaseWithdrawn

First Approval Date

United States (10 Aug 2001),

Acute decompensated heart failure

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 37334

Source: *****

This study is a single-center, retrospective analysis of 105 pediatric patients with RSV infection. The patients were divided into two groups: those with cardiovascular events and those without. Logistic regression analyses were conducted to identify independent risk factors for cardiovascular events in children with RSV infection. The predictive value of these factors for cardiovascular events in RSV-infected children was evaluated using the area under the curve.

RESULTS:

Compared to the group without cardiovascular events, the group with cardiovascular events showed significantly higher levels of NLR, BNP, BUN, D-dimer, and required higher scores for vasopressor use, higher oxygen concentrations, and a higher proportion of respiratory support. And had longer PICU stays and higher hospitalization costs. Logistic analyses identified pulmonary consolidation and BNP as independent risk factors for cardiovascular events in RSV-infected children. When pulmonary consolidation and BNP were used in combination for prediction, the AUC increased to 0.858.

CONCLUSION:

The combination of pulmonary consolidation and BNP has a higher predictive value for the occurrence of cardiovascular events in children with RSV infection.

01 Nov 2025·JOURNAL OF CLINICAL NEUROSCIENCE

Early diagnostic utility of BNP and NT-proBNP for cardioembolic stroke: A head-to-head comparison in the hyperacute and early acute phase

Article

Author: Chae, Hyojin ; Lee, Jeong-Joong ; Han, Eunhee ; Kim, Hyejeong ; Oh, Eun-Jee ; Choi, Ae-Ran ; Kwon, Minseok

BACKGROUND:

Cardioembolic (CE) stroke is a common and often severe subtype of ischemic stroke, but early and accurate differentiation from other stroke types remains challenging. Brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) have emerged as promising biomarkers, yet direct comparative studies evaluating their diagnostic utility in the hyperacute and early acute phase are limited.

METHODS:

This prospective study included 165 patients who presented with acute stroke symptoms within twenty-four hours of onset at a single tertiary center. Plasma BNP and NT-proBNP levels were measured upon admission and analyzed in relation to stroke subtype, with classification based on TOAST criteria. Diagnostic performance for identifying CE stroke was evaluated using receiver operating characteristic (ROC) curve analysis.

RESULTS:

Among 121 patients diagnosed with ischemic stroke, 32 (26.4 %) had CE stroke. Both BNP and NT-proBNP levels were significantly higher in CE stroke compared to other subtypes. ROC analysis showed that BNP (AUC = 0.845) and NT-proBNP (AUC = 0.861) demonstrated similar diagnostic accuracies. A BNP cutoff of 49.8 pg/mL achieved a sensitivity of 87.5 % and specificity of 79.0 %, while an NT-proBNP cutoff of 350 pg/mL yielded a sensitivity of 90.6 % and specificity of 75.2 %.

CONCLUSION:

Our results demonstrate that BNP and NT-proBNP provide similar diagnostic accuracy for distinguishing CE stroke in the hyperacute and early acute setting. Their high sensitivity in hyperacute and early acute phase highlights the potential of both biomarkers to improve diagnostic accuracy, especially in setting with limited healthcare resources.

01 Oct 2025·JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS

Mechanical Evaluation of Boron Nanoparticle‐Modified Silicone Elastomers for Maxillofacial Prostheses

Article

Author: Akay, Canan ; Altuntaş, Naim Berker ; Avukat, Esra Nur

ABSTRACT:

This study evaluated the effects of boron nanoparticles (BNPs) on the mechanical properties of two silicone elastomers, A‐2000 and A‐2006. Tensile, tear, hardness, and elongation tests were conducted in accordance with ASTM and ISO standards. A total of 180 specimens were prepared, comprising control groups without BNPs and experimental groups containing 1 and 3 wt% BNPs. Tensile and tear strength tests were performed using a device with a 1 kN capacity at a crosshead speed of 100 mm/min; hardness was measured using Shore A tests, and Atomic Force Microscopy (AFM) was employed to assess surface roughness. Tensile testing revealed that the A‐2000 control group exhibited the highest tensile strength, with significant reductions observed in both BNP‐incorporated subgroups. In A‐2006, tensile strength decreased significantly with 1 wt% BNPs but partially recovered at 3 wt%. Tear strength in A‐2000 significantly decreased at 1 wt% but returned to control levels at 3 wt%, whereas no statistically significant differences were observed among the A‐2006 subgroups. Hardness significantly increased with 3 wt% BNPs in A‐2000 and with both 1 and 3 wt% BNPs in A‐2006. Regarding elongation, A‐2000 showed no significant change compared with the control, although the 1 and 3 wt% groups differed significantly from each other. In A‐2006, both 1 and 3 wt% BNP groups showed significant reductions in elongation compared with the control. Overall, A‐2000 exhibited superior tensile and tear strength, while A‐2006 demonstrated greater elongation capacity. These findings indicate that BNP incorporation depends on both the elastomer type and concentration, with potential trade‐offs between improved hardness and decreased flexibility. Both A‐2000 and A‐2006 remain viable options for maxillofacial prostheses, although optimization of BNP concentration is essential to balance strength, durability, and flexibility.

2

News (Medical) associated with Nesiritide Recombinant

19 Oct 2023

·www.sciencedaily.com

BNP peptide a culprit in eczema

Researchers have pinpointed a particular peptide's role in activating atopic dermatitis, or eczema. The work could lead to more effective treatments for the condition. Researchers from North Carolina State University have pinpointed a particular peptide's role in activating atopic dermatitis, or eczema. The work could lead to more effective treatments for the condition. Atopic dermatitis (AD) is a skin condition characterized by itching, irritated and thickened skin at the site of the irritation. The brain natriuretic peptide (BNP) is a peptide, or short chain of amino acids, that is elevated in patients with AD. "BNP is expressed in sensory neurons, the neurons responsible for conveying sensation to the brain via the spinal cord," says Santosh Mishra, associate professor of molecular biomedical sciences at NC State and corresponding author of the work. "We know from previous work that BNP helps translate the sensation of itch from the skin to the brain. In this work we wanted to see if BNP was involved in activating AD." In a chemically induced mouse model of AD, the researchers saw that mice without BNP did not exhibit the thickened or irritated skin commonly associated with AD, and their itching was reduced compared with control mice who did have BNP. "The results show that BNP likely plays a role in itch activation," Mishra says. "We next looked at BNP's relationship to periostin, to see if we could determine how that activation takes place." Periostin is a protein that can interact with sensory neurons in skin to activate itch response. It is produced in skin cells called keratinocytes and fibroblasts. Keratinocytes in turn, have receptors for BNP, which are called NPR1 receptors. When the BNP receptors are activated, periostin is produced and itch can be turned on. "But the interesting thing here is that the sensory neurons are the activator," Mishra says. The neuron releases BNP, which activates keratinocytes with the NPR1 receptor, which then release the periostin. "This work shows that peripheral neurons, not just central neurons, are playing a role in AD -- it begins in the sensory neurons, and cascades from there," Mishra adds. "It also points to some potential therapeutic strategies, such as blocking BNP's ability to bind to NPR1 receptors in the skin." The research appears as a letter to the editor in the Oct. 11 issue of the Journal of Investigative Dermatology. The work was supported by the National Institutes of Health under grant number 1R56AR077692-01. NC State undergraduate student Junho Yu, former NC State undergraduate student Nidha Williams, and NC State postdoctoral research scholar Joshua Wheeler, also contributed to the work.

26 Apr 2023

·www.prnewswire.com

The Role of Natriuretic Peptides in the Diagnosis and Management of Heart Failure Discussed in New Joint Scientific Statement by the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, and Japanese Heart Failure Society

ROCKVILLE, Md., April 26, 2023 /PRNewswire/ -- The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA-ESC) and the Japanese Heart Failure Society (JHFS) announced today a joint scientific statement on Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure. Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP), are internationally used as a biomarker for diagnosis and management in adults with heart failure (HF). In addition, natriuretic peptide biomarker data can be important in risk stratification of heart failure prognosis. In addition to biomarker data, implementation of an oral angiotensin receptor neprilysin inhibitor (ARNI) has increased healthcare professionals' awareness of natriuretic peptides as an important therapeutic agent. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure scientific statement aims to provide a framework and expert recommendations to healthcare professionals on the diagnosis and management of HF and focuses on the following areas: History and basic research: discovery, production, and cardiovascular protection Diagnostic and prognostic biomarkers: acute HF, chronic HF, inclusion/endpoint in clinical trials, and natriuretic peptides-guided therapy Therapeutic use: nesiritide (BNP), carperitide (ANP), and sacubitril (neprilysin inhibitor [combined with an angiotensin receptor blocker]), and Gaps in knowledge and future directions Standardized screening for HF remains challenging because of the heterogeneity of risk factors across different patient populations. Natriuretic peptides are recommended for initial diagnosis of HF as noted in the 2022 ACC/AHA/HFSA Guideline for the Management of HF, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF, and JCS2017/JHF2017 Guideline on diagnosis and treatment of acute and chronic HF. "There are several differences in the statements among HF Societies regarding the use of natriuretic peptides as biomarkers for risk stratification and prevention. The scientific statement provides up-to-date perspectives and guidance that healthcare professionals can use to navigate and provide the best care for their patients with HF," Nancy Albert, PhD, CCNS, CHFN; co-chair and co-author representing HFSA in the Trilateral International Consensus Conference (TICC) said. The joint scientific statement on natriuretic peptides was developed by the TICC, a collaboration of HFSA, JHFS and HFSA-ESC. The TICC 2021 was hosted by the JHFS and was chaired by Hiroyuki Tsutsui, President of the JHFS, with Nancy M. Albert (HFSA) and Andrew Coats (HFA-ESC) serving as co-chairs. The Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure scientific statement will jointly publish on Monday 17 April at 9:00 AM EDT in the Journal of Cardiac Failure, the official journal of the HFSA and the JHFS, and the European Journal of Heart Failure, the official journal of the HFA-ESC. DOI: 10.1016/j.cardfail.2023.02.009 To receive a copy of the manuscript in advance of the embargo, contact [email protected]. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. About the Heart Failure Association of the European Society of Cardiology As the world's largest heart failure association, the Heart Failure Association of the ESC prioritizes patient management and awareness of heart failure as a global health problem. HFA-ESC's mission is to improve quality of life and longevity through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research. Learn more online. About the Japanese Heart Failure Society In response to the increased interest in heart failure, based on the basic studies on its mechanisms and clinical trials, the Japanese Heart Failure Society (JHFS) was established in 1996. The first General and Scientific Meeting of the JHFS was held in October 1997 at the Kyoto International Conference Center. The number of members increased from 900 to approximately 4000 in 2020. The vision of JHFS is to enrich the happy life of the patients and their families through investigating the basic pathophysiology of heart failure, and developing the effective and efficient diagnosis, prevention and treatment strategies. About the Journal of Cardiac Failure The Journal of Cardiac Failure (JCF) publishes the highest quality science in the field of heart failure with a focus on diversity, equity, and inclusion, mentorship, multidisciplinary partnerships, and patient-centeredness. Published papers span original investigator-initiated work to state-of-the-art reviews, guidelines and scientific statements, expert perspectives, early career and trainee spotlight pieces, patient and patient-partner narratives. JCF also emphasizes the power of language and prioritizes innovative approaches to dissemination of published work to reach and impact the broader heart failure community. For more information, visit onlinejcf.com. About the European Journal of Heart Failure The European Journal of Heart Failure (EJHF) is dedicated to the advancement of knowledge in the field of heart failure management. The journal publishes reviews and editorials to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as clinical, social and population sciences all form part of the discipline. Visit EJHF online. Media Contact: Laura Poko: Director of Marketing and Communications, Heart Failure Society of America, 301-798-4493, ext. 226 [email protected] Olivia Seward: Associate Director Communication, European Society of Cardiology, +33 (0)4 89 87 20 10, [email protected] SOURCE Heart Failure Society of America

100 Deals associated with Nesiritide Recombinant

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nesiritide Recombinant	C01DX19	DB04899

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute decompensated heart failure	United States	Scios LLC	10 Aug 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Artery Disease	Phase 3	-	Scios, Inc.	17 Sep 2007
Pulmonary Disease, Chronic Obstructive	Phase 3	Australia	Janssen-Cilag Pty Ltd.	01 Sep 2007
Cardiomyopathies	Phase 3	-	Scios, Inc.	01 Jan 2001
Dyspnea, Paroxysmal	Phase 3	-	Scios, Inc.	01 Jan 2001
Acute congestive heart failure	Phase 3	-	Scios, Inc.	01 Oct 1999
Decompensated chronic heart failure	Phase 3	-	Scios, Inc.	01 Oct 1999
Heart failure NYHA class IV	Phase 3	-	Scios, Inc.	01 Aug 1998
Chronic congestive heart failure	Phase 3	-	Scios, Inc.	01 Oct 1996
Heart Failure	Phase 3	-	Scios, Inc.	01 Oct 1996
Ventricular Dysfunction, Left	Phase 2	United States	Scios, Inc.	01 Mar 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00281671 (CTgov)	Phase 1/2	Heart Defects, Congenital	9	Placebo (Placebo)	bzpgccowtk(myhcslzgnf) = ljsouqmrrm pqkufubdve (bbfwshpcyt, suadoigdnt - gqvxczxhiw) View more	-	27 Aug 2020
				nesiritide (Nesiritide)	bzpgccowtk(myhcslzgnf) = tmqxfaeihw pqkufubdve (bbfwshpcyt, vhbnhldhxt - zkuuooebvs) View more
NCT00543309 (CTgov)	Phase 2	Heart Defects, Congenital	106	nesiritide (I- Nesiritide)	gpsjkshdzw(qqkvtxsnzf) = lstdsccyux wvovcxxboj (xsjpqaiaub, bfhgvkjkbs - nkmsiblbou) View more	-	25 Jun 2018
				milrinone (II- Milrinone)	gpsjkshdzw(qqkvtxsnzf) = wzprxrjnmz wvovcxxboj (xsjpqaiaub, kxgugusuxe - vmoajqqdsj) View more
NCT00475852 (ASCEND-HF, Pubmed \| Circ Heart Fail)	Phase 3	Acute decompensated heart failure	7,141	Nesiritide (High enrolling sites)	pjmkwyqrtr(ifeozrtscz): hazard ratio = 0.99 (95% CI, 0.98 - 1.01) View more	-	01 Sep 2016
				Nesiritide (Low enrolling sites)
NCT00475852 (ASCEND-HF, Pubmed \| BMJ Open)	Phase 3	Heart Failure	1,068	Nesiritide (Self-presentation)	lqxheqhopa(ilputsjexu) = vkxsiafeml uewfydnecb (dcttpsgovp ) View more	-	17 Mar 2016
				Nesiritide (Ambulance)	lqxheqhopa(ilputsjexu) = dpgoniblwt uewfydnecb (dcttpsgovp ) View more
NCT00475852 (ASCEND-HF, Pubmed \| J Am Heart Assoc)	Phase 3	Heart Failure \| Atrial Fibrillation	7,007	nesiritide (Patients with AF)	acenooqnrx(sdvqgjnzrv) = ghxmzeinvk diloynjpil (itzuatifur )	-	24 Aug 2015
				nesiritide (Patients without AF)	acenooqnrx(sdvqgjnzrv) = ryoahbuvqn diloynjpil (itzuatifur )
NCT01544998 (CTgov)	Phase 1/2	Depressive Disorder \| Heart Failure \| Renal Insufficiency	43	Tadalafil+Nesiritide (Tadalafil Plus Nesiritide)	qsueipslqn(skmdvzjtlt) = kbpqxdysqv vgezgzinrh (dmnyhrgnsg, 161.8) View more	-	04 Mar 2015
				Placebo+Tadalafil (Tadalafil Plus Placebo)	qsueipslqn(skmdvzjtlt) = ifaziqqmgv vgezgzinrh (dmnyhrgnsg, 86.5) View more
NCT00475852 (ASCEND-HF, Pubmed \| Circulation)	Phase 3	Acute decompensated heart failure	7,141	Nesiritide	tsvliqccjq(qbpmroebzv) = ohpghuujje moyzklxvrq (nwrvlfkihk ) View more	-	16 Sep 2014
				Placebo	tsvliqccjq(qbpmroebzv) = siorqioyle moyzklxvrq (nwrvlfkihk ) View more
NCT00573144 (Believe II, CTgov)	Phase 2	Anterior Wall Myocardial Infarction \| Acute myocardial infarction	59	Placebo (Placebo)	vrxlbfrvsi(tlyqfrljet) = flpukubntr lpnlysdvhx (gdoedwnmxm, 58) View more	-	09 Sep 2014
				Nesiritide (Nesiritide)	vrxlbfrvsi(tlyqfrljet) = qceuqdfosp lpnlysdvhx (gdoedwnmxm, 31) View more
NCT01132846 (ROSE/RED ROSE \| ROSE, CTgov)	Phase 2	Dyspnea \| Heart Failure	360	Dopamine (Low Dose Dopamine)	elnkvadtcr(feqkjbhjmb) = fwatruvakv jiigyaxbkz (oanxikmvov, .32) View more	-	21 Aug 2014
				Placebo (Placebo)	elnkvadtcr(feqkjbhjmb) = ggxvqwwolj jiigyaxbkz (oanxikmvov, .27) View more
NCT01836809 (CTgov)	Phase 4	Cardio-Renal Syndrome	2	nesiritide (Total Artificial Heart)	dfezxklcso(sytulzesis) = gyvtzdhtja tgzckowdjl (uantbefixd, obewjvmmek - uuegqzicsn) View more	-	18 Aug 2014
				placebo (Total Artificial Heart: Placebo)	dfezxklcso(sytulzesis) = tmdysehjjo tgzckowdjl (uantbefixd, isfrzurmxi - ekqsfzbvnh) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data